Eberconazole--pharmacological and clinical review.

[1]  T. Vinuesa,et al.  Characterization of the antimicrobial susceptibility of fungi responsible for onychomycosis in Spain. , 2010, Medical mycology.

[2]  Alix J Charles.  Original Article: Superficial cutaneous fungal infections in tropical countries , 2009, Dermatologic therapy.

[3]  M. Friedrich,et al.  Epidemiological trends in skin mycoses worldwide , 2008, Mycoses.

[4]  M. Gratacós,et al.  Eberconazole 1% cream is an effective and safe alternative for dermatophytosis treatment: multicenter, randomized, double‐blind, comparative trial with miconazole 2% cream , 2006, International journal of dermatology.

[5]  J. Guarro,et al.  In Vitro Activities of the New Antifungal Drug Eberconazole and Three Other Topical Agents against 200 Strains of Dermatophytes , 2003, Journal of Clinical Microbiology.

[6]  A. Rubin,et al.  Six Novel Antimycotics , 2002, American journal of clinical dermatology.

[7]  A. del Palacio,et al.  A double‐blind randomized comparative trial: eberconazole 1% cream versus clotrimazole 1% cream twice daily in Candida and dermatophyte skin infections , 2001, Mycoses.

[8]  B. Elewski,et al.  Guidelines of care for superficial mycotic infectionsof the skin: Tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis , 1996 .

[9]  A. R. Noriega,et al.  Topical treatment of tinea corporis and tinea cruris with eberconazole (WAS 2160) cream 1% and 2%: a phase II dose‐finding pilot study , 1995, Mycoses.

[10]  J. Ernest.  Topical antifungal agents. , 1992, Obstetrics and gynecology clinics of North America.